David A. Siegel Insmed Inc Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Insmed Inc stock. As of the latest transaction made, Two Sigma Advisers, LP holds 392,700 shares of INSM stock, worth $27.3 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares

392,700

Previous 295,400 32.94%

Holding current value

$27.3 Million

Previous $19.8 Million 44.85%

% of portfolio

0.07%

Previous 0.05%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$62.0 - $79.01 $6.03 Million - $7.69 Million	97,300 Added 32.94%	392,700 $28.7 Million
Q2 2024 Aug 14, 2024	SELL	$22.0 - $69.71 $9.26 Million - $29.3 Million	-421,000 Reduced 58.77%	295,400 $19.8 Million
Q1 2024 May 15, 2024	BUY	$25.72 - $29.94 $2.24 Million - $2.61 Million	87,200 Added 13.86%	716,400 $19.4 Million
Q4 2023 Feb 14, 2024	SELL	$23.42 - $31.74 $4.6 Million - $6.23 Million	-196,200 Reduced 23.77%	629,200 $19.5 Million
Q3 2023 Nov 14, 2023	BUY	$19.86 - $26.93 $5.09 Million - $6.9 Million	256,300 Added 45.04%	825,400 $20.8 Million
Q2 2023 Aug 14, 2023	BUY	$16.44 - $21.1 $1.97 Million - $2.53 Million	120,100 Added 26.75%	569,100 $12 Million
Q1 2023 May 15, 2023	BUY	$16.26 - $21.73 $2.28 Million - $3.04 Million	140,000 Added 45.31%	449,000 $7.66 Million
Q4 2022 Feb 14, 2023	BUY	$16.98 - $23.15 $2.03 Million - $2.77 Million	119,500 Added 63.06%	309,000 $6.17 Million
Q3 2022 Nov 14, 2022	BUY	$20.88 - $28.21 $1.77 Million - $2.39 Million	84,700 Added 80.82%	189,500 $4.08 Million
Q2 2022 Aug 15, 2022	SELL	$17.07 - $25.71 $1.3 Million - $1.95 Million	-75,900 Reduced 42.0%	104,800 $2.07 Million
Q1 2022 May 16, 2022	SELL	$20.42 - $28.13 $455,366 - $627,299	-22,300 Reduced 10.99%	180,700 $4.25 Million
Q4 2021 Feb 14, 2022	SELL	$25.89 - $33.45 $5.9 Million - $7.62 Million	-227,700 Reduced 52.87%	203,000 $5.53 Million
Q3 2021 Nov 15, 2021	BUY	$22.46 - $29.47 $4.3 Million - $5.64 Million	191,300 Added 79.91%	430,700 $11.9 Million
Q2 2021 Aug 16, 2021	BUY	$24.17 - $36.01 $2.75 Million - $4.1 Million	113,800 Added 90.61%	239,400 $6.81 Million
Q1 2021 May 17, 2021	BUY	$32.28 - $44.3 $1.67 Million - $2.29 Million	51,700 Added 69.96%	125,600 $4.28 Million
Q4 2020 Feb 16, 2021	SELL	$31.45 - $40.54 $3.23 Million - $4.16 Million	-102,700 Reduced 58.15%	73,900 $2.46 Million
Q3 2020 Nov 16, 2020	BUY	$26.0 - $34.5 $1.44 Million - $1.9 Million	55,200 Added 45.47%	176,600 $5.68 Million
Q2 2020 Aug 14, 2020	BUY	$14.11 - $29.42 $358,394 - $747,268	25,400 Added 26.46%	121,400 $3.34 Million
Q1 2020 May 15, 2020	SELL	$13.63 - $33.98 $216,717 - $540,282	-15,900 Reduced 14.21%	96,000 $1.54 Million
Q4 2019 Feb 14, 2020	SELL	$16.12 - $24.98 $1.16 Million - $1.8 Million	-72,000 Reduced 39.15%	111,900 $2.67 Million
Q3 2019 Nov 14, 2019	BUY	$15.49 - $25.78 $1.08 Million - $1.8 Million	69,900 Added 61.32%	183,900 $3.24 Million
Q2 2019 Aug 14, 2019	BUY	$23.0 - $32.19 $2.1 Million - $2.94 Million	91,400 Added 404.42%	114,000 $2.92 Million
Q1 2019 May 15, 2019	BUY	$13.91 - $31.15 $314,366 - $703,990	22,600 New	22,600 $657,000
Q4 2018 Feb 14, 2019	SELL	$11.6 - $18.7 $157,760 - $254,320	-13,600 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$18.95 - $28.08 $56,850 - $84,240	3,000 Added 28.3%	13,600 $275,000
Q2 2018 Aug 14, 2018	BUY	$20.0 - $29.72 $26,000 - $38,636	1,300 Added 13.98%	10,600 $251,000
Q1 2018 May 15, 2018	BUY	$21.69 - $32.99 $201,717 - $306,807	9,300 New	9,300 $209,000
Q4 2017 Feb 14, 2018	SELL	$26.43 - $31.78 $190,296 - $228,816	-7,200 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$11.61 - $31.21 $83,592 - $224,712	7,200	7,200 $225,000

Others Institutions Holding INSM

# of Institutions

466

Shares Held

180M

Call Options Held

2.27M

Put Options Held

3.33M

View Full List

About INSMED Inc

Ticker INSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,476,992
Market Cap $9.43B
Description
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...

More about INSM

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account